Literature DB >> 2944983

T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity.

A DiGiacomo, R J North.   

Abstract

The results of this study show that during growth of the immunogenic Meth A fibrosarcoma, two different types of suppressor T lymphocytes are generated in sequence. One type is generated during early tumor growth, reaches peak number around day 6, and is progressively lost thereafter. It is defined by its ability, upon passive transfer, to suppress the expression of a DTH reaction to tumor antigens in tumor-immunized recipients. It bears the Ly1-,2+ membrane phenotype and is sensitive to relatively low doses of cyclophosphamide. In contrast, the second type of suppressor cell is not detected until after day 9 of tumor growth, and is defined by its ability to inhibit, upon passive transfer, the expression of adoptive immunity against an established tumor in T cell-deficient recipients. According to previous studies it bears the Ly1+,2-, L3T4a+ membrane phenotype and is less sensitive to cyclophosphamide than the T cell suppressor of DTH. It is argued that this second type of suppressor T cell seems likely to be responsible for the escape of immunogenic tumors from antitumor immunity, because it can suppress the expression of a powerful mechanism of antitumor immunity in recipient mice, and is generated progressively as the tumor-bearing host loses concomitant immunity. In contrast, although the Ly-1-,2+ T cell suppressors of DTH can efficiently suppress a DTH reaction to an implant of living tumor cells, they fail to suppress the expression of immunity to the same implant.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944983      PMCID: PMC2188402          DOI: 10.1084/jem.164.4.1179

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.

Authors:  S Fujimoto; M I Greene; A H Sehon
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

2.  Tumor bearer T cells suppress BCG-potentiated antitumor responses. I. Requirements for their effect.

Authors:  E Hawrylko
Journal:  Cell Immunol       Date:  1982-01-01       Impact factor: 4.868

3.  Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

Authors:  D P Dialynas; Z S Quan; K A Wall; A Pierres; J Quintáns; M R Loken; M Pierres; F W Fitch
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

4.  Tumor bearer T cells suppress BCG-potentiated antitumor responses II. Characteristics of the efferent phase suppressor.

Authors:  E Hawrylko; C A Mele; O Stutman
Journal:  Cell Immunol       Date:  1982-01-01       Impact factor: 4.868

Review 5.  The genetic and cellular basis of regulation of the immune response to tumor antigens.

Authors:  M I Greene
Journal:  Contemp Top Immunobiol       Date:  1980

6.  Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.

Authors:  E S Dye; R J North
Journal:  J Leukoc Biol       Date:  1984-07       Impact factor: 4.962

7.  Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations.

Authors:  E S Dye; R J North; C D Mills
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

8.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.

Authors:  M J Berendt; R J North
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

9.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

10.  Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.

Authors:  R J North; I Bursuker
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  10 in total

Review 1.  The role of contrasuppression in tumor regression.

Authors:  P M Flood; A Friedman; J Freedman; B Horvat; P Reuter; W Ptak
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

2.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Comparative methodologies of regulatory T cell depletion in a murine melanoma model.

Authors:  Norimasa Matsushita; Shari A Pilon-Thomas; Lisa M Martin; Adam I Riker
Journal:  J Immunol Methods       Date:  2008-02-13       Impact factor: 2.303

4.  Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors.

Authors:  C Garlanda; C Parravicini; M Sironi; M De Rossi; R Wainstok de Calmanovici; F Carozzi; F Bussolino; F Colotta; A Mantovani; A Vecchi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

5.  Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s).

Authors:  F R Khakpour; J W Murphy
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

Review 6.  Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.

Authors:  Jay M Lee; Jane Yanagawa; Katherine A Peebles; Sherven Sharma; Jenny T Mao; Steven M Dubinett
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-04       Impact factor: 6.312

Review 7.  Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy.

Authors:  S Dray; M B Mokyr
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 8.  The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps.

Authors:  Silvia Gitto; Ambra Natalini; Fabrizio Antonangeli; Francesca Di Rosa
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

9.  Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Authors:  Mary Jo Turk; José A Guevara-Patiño; Gabrielle A Rizzuto; Manuel E Engelhorn; Shimon Sakaguchi; Alan N Houghton
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

10.  Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma.

Authors:  K Naito; T Oka; S Nomi; H Yamagishi; B D Kahan
Journal:  Jpn J Cancer Res       Date:  1989-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.